Exxe Group Acquires MMeditech GmbH

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

October 5, 2020

Exxe Group, Inc. a diversified company focused on synergistic acquisitions in critical, fast-growing industries, has acquired a controlling interest in Swiss medical supply company MMeditech GmbH*. MMeditech’s primary revenue drivers are focused on the provision of globally sourced, high-use consumable medical supplies. These include hygiene products, syringes, bandages, and sterilization materiel.

Exxe Group reported among other elements, the MMeditech acquisition brings immediate revenues to Exxe, a high level of operating profitability, and a backlog of $2.8 million for 2021. The company is also engaged in other related health care product sales and product development which could bear considerable fruit in future quarters.

MMeditech GmbH is currently on track to generate revenues of $2.7 million in 2020 and is targeting revenues of $3.6 million and EBITDA of $1.2M in 2021. By comparison, in 2019 the company generated revenues of $869K with EBITDA of $328K.

Year

Revenue

EBITDA

2019A

$869,820

328,090

2020E

$2,725,000

782,620

2021E

$3,597,000

1,238,240

Eduard Nazmiev, Ph.D., CEO, and President of Exxe Group commented: “MMeditech GmbH is AXXA’s first medical supply company acquisition and further solidifies our $30.8 million revenue estimate for FY2021. The acquisition provides Exxe with a channel to leverage its existing medical supply chain relationships in order to grow MMeditech’s revenues and global supply chain footprint.”

*Dr. Martin Horst founded MMeditech in 2004 as a sole proprietorship before incorporating as MMeditech GmbH in 2019. The company services the Swiss B2B medical supply market with globally sourced medical supply products. In addition, it is a financial partner at all stages of venture and post-venture, private, and public – partnering in the biotech sector.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.